BTIG Research Reaffirms “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reaffirmed by analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock. BTIG Research’s price target would suggest a potential upside of 191.55% from the company’s current price.

Several other analysts have also recently weighed in on NRXP. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. D. Boral Capital reissued a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Tuesday, May 5th. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 10th. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Ascendiant Capital Markets increased their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the company a “buy” rating in a report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.50.

NRx Pharmaceuticals Trading Up 4.9%

Shares of NASDAQ:NRXP opened at $3.43 on Tuesday. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $5.05. The stock has a market cap of $124.27 million, a P/E ratio of -6.24 and a beta of 2.18. The company has a 50 day moving average of $3.78 and a 200 day moving average of $2.97.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million. On average, equities analysts forecast that NRx Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of large investors have recently bought and sold shares of NRXP. Anson Funds Management LP boosted its stake in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after purchasing an additional 1,018,853 shares during the period. Commonwealth Equity Services LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth approximately $994,000. Bleakley Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the fourth quarter worth $318,000. AdvisorShares Investments LLC increased its stake in shares of NRx Pharmaceuticals by 28.2% in the first quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock worth $896,000 after buying an additional 92,463 shares during the period. Finally, Vanguard Group Inc. raised its holdings in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.